Recent developments in the use of chemotherapy in brain tumours

European Journal of Cancer

Volumn 42, Issue 5, 2006, Pages 582-588

  Van Den Bent, Martin J ^a   Hegi, Monika E ^b   Stupp, Roger ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Anaplastic glioma; Glioblastoma; MGMT; Oligodendroglioma; PCV; Radiotherapy; Temozolomide

Indexed keywords

ANTICONVULSIVE AGENT; CARMUSTINE; CISPLATIN; CORTICOSTEROID; COTRIMOXAZOLE; DNA; ERLOTINIB; IRINOTECAN; MARIMASTAT; NITROSOUREA; PENTAMIDINE; PROCARBAZINE; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID; TEMOZOLOMIDE; THALIDOMIDE; VATALANIB;

ANAPLASTIC CARCINOMA; ANTIBIOTIC PROPHYLAXIS; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BRAIN TUMOR; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CD4 LYMPHOCYTE COUNT; CHEMOSENSITIVITY; CLINICAL TRIAL; COGNITIVE DEFECT; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DISEASE FREE INTERVAL; DNA ADDUCT; DNA ALKYLATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DOSE REGIMEN; DRUG PENETRATION; DRUG TOLERABILITY; GENE SILENCING; GERIATRIC PATIENT; GLIOBLASTOMA; GLIOMA; HETEROZYGOSITY LOSS; HUMAN; IMMUNE DEFICIENCY; KAPOSI SARCOMA; LYMPHOCYTOPENIA; OLIGODENDROGLIOMA; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROMOTER REGION; RADIATION DOSE FRACTIONATION; REVIEW; SURVIVAL RATE; SURVIVAL TIME;

EID: 33644775576     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.06.031     Document Type: Article

References (63)

1. M.D. Walker, E. Alexander, and W.E. Hunt Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial J Neurosurg 49 1978 333 343
2. M.D. Walker, S.B. Green, and D.P. Byar Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery N Engl J Med 303 1980 1323 1329
3. Glioma Meta-Analysis Group Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials Lancet 359 2002 1011 1018
4. R. Stupp, W.P. Mason, and M.J. van den Bent Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996
5. S. Ostermann, C. Csajka, and T. Buclin Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients Clin Cancer Res 10 2004 3728 3736
6. M. Brada, I. Judson, and P. Beale Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies Br J Cancer 81 1999 1022 1030
7. S.L. Gerson MGMT: its role in cancer aetiology and cancer therapeutics Nature Rev 4 2004 296 307
8. L. Liu, E. Allay, and L.L. Dumenco Rapid repair of O6-methylguanine-DNA adducts protects transgenic mice from N-methylnitrosourea-induced thymic lymphomas Cancer Res 54 1994 4648 4652
9. M. Belanich, T. Randall, and M.A. Pastor Intracellular localization and intracellular heterogeneity of the human DNA repair protein 06-methylguanine-DNA methyltransferase Cancer Chemother Pharm 37 1996 547 555
10. K.A. Jaeckle, H.J. Eyre, and J.J. Townsend Correlation of tumour O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a southwest oncology group study J Clin Oncol 16 1999 3310 3315
11. M. Belanich, M. Pastor, and T. Randall retrospective study of the correlation between DNA repair protein alkyltransferase and survival of brain tumour patients treated with carmustine Cancer Res 56 1996 783 788
12. J.R. Silber, B.A. Mueller, and T.G. Eweres Comparison of O6-methylguanine-DNA methyltransferase activity in brain tumours and in adjacent normal brain Cancer Res 53 1993 3416 3420
13. M. Esteller, J. Garcia-Foncillas, and E. Andion Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents N Engl J Med 343 2000 1350 1354
14. M.E. Hegi, A.-C. Diserens, and S. Godard Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide Clin Cancer Res 15 2004 1871 1874
15. W.K.A. Yung, M. Prados, and R. Yaya-Tur Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse J Clin Oncol 17 1999 2762 2771
16. W.K.A. Yung, R.E. Albright, and J. Olson A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse Br J Cancer 83 2000 588 593
17. M. Brada, K. Hoang-Xuan, and R. Rampling Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse Ann Oncol 12 2000 259 266
18. C.S. Brock, E.S. Newlands, and S.R. Wedge Phase I trial of Temozolomide using an extende continuous oral schedule Cancer Res 58 1998 4363 4367
19. K. Vera, L. Djafari, and S. Faivre Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumours Ann Oncol 15 2004 161 171
20. T.P. Spiro, L. Liu, and S. Majka Temozolomide: the effect of once- and twice-a-day dosing on tumour tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase Clin Cancer Res 7 2001 2309 2317
21. A.W. Tolcher, S.L. Gerson, and L. Denis Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules Br J Cancer 88 2003 1004 1011
22. R.B. Khan, J.J. Raizer, and M.G. Malkin A phase II study of extended low-dose temozolomide in recurrent malignant gliomas Neuro-Oncology 4 2002 39 43
23. W. Wick, J.P. Steinbach, and W.M. Küker One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma Neurology 62 2004 2113 2115
24. Y.B. Su, S. Sohn, and S.E. Krown Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications J Clin Oncol 15 2004 610 616
25. A.K. Mahindra, and S.A. Grossman Pneumocystis carinii pneumonia in HIV negative patients with primary brain tumours J Neuro-Oncol 63 2003 263 270
26. R. Stupp, P.-Y. Dietrich, and S. Osterman-Kraljevic Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide J Clin Oncol 20 2002 1375 1382
27. M.E. Hegi, A.-C. Diserens, and T. Gorlia MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 2005 997 1003
28. H.S. Friedman, R.E. McLendon, and T. Kerby DNA mismatch repair and 06-alkylguanine-DNA alkyltransferase and response to temodal in newly diagnosed malignant glioma J Clin Oncol 16 1998 3851 3857
29. O.-L. Chinot, M. Barrie, and E. Frauger Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in elderly populations Cancer 100 2004 2208 2214
30. M. Glantz, M. Chamberlain, and Q. Liu Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas Cancer 97 2003 2262 2266
31. W. Roa, P.M.A. Brasher, and G. Bauman Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial J Clin Oncol 22 2004 1583 1588
32. E.L. Chang, W. Yi, and P.K. Allen Hypofractionated radiotherapy for elderly or younger low-performance status glioblastoma patients: outcome and prognostic factors Int J Radiat Oncol Biol Phys 56 2003 519 528
33. A.A. Brandes, U. Basso, and M. Reni First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia J Clin Oncol 22 2004 1598 1604
34. M.D. Groves, V.K. Puduvalli, and K.R. Hess Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme J Clin Oncol 20 2002 1383 1388
35. K.A. Jaeckle, K.R. Hess, and W.K.A. Yung Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumour Consortium Study J Clin Oncol 21 2003 2305 2311
36. H.A. Fine, P.Y. Wen, and E.A. Maher Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas J Clin Oncol 21 2003 2299 2304
37. 6-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma J Clin Oncol 20 2002 2277 2283
38. S. Clifford Schold Jr., J.G. Kuhn, and S.M. Chang A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North-American brain tumour consortium study Neuro-Oncology 2 2000 34
39. 6-benzylguanine for patients with recurrent or progressive malignant glioma J Clin Oncol 18 2000 3522 3528
40. J.A. Quinn, A. Desjardins, and D. Reardon Phase II trial of temozolomide (temodar) plus O6-benzylguanine in the treatment of patients with temodar-resistant malignant glioma Neuro-Oncology 6 2004 380 (Abstract TA-45)
41. M.D. Prados, W.K.A. Yung, and H.A. Fine Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumour Consortium study Neuro-Oncology 6 2004 33 37
42. H.S. Friedman, W.P. Petros, and A. Friedman Irinotecan therapy in adults with recurrent or progressive malignant glioma J Clin Oncol 17 1999 1516 1525
43. E. Raymond, M. Fabbro, and V. Boige Multicentre phase II study abd pharmacokinetic analysis of irinotecan in chemotherapy-naÏve patients with glioblastoma Ann Oncol 14 2003 603 614
44. M. Chamberlain Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme J Neuro-Oncol 56 2002 183 188
45. G. Cairncross, D. Macdonald, and S. Ludwin Chemotherapy for anaplastic oligodendroglioma J Clin Oncol 12 1994 2013 2021
46. M.J. van den Bent, J.M. Kros, and J.J. Heimans Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU and vincristine chemotherapy Neurology 51 1998 1140 1145
47. M. Möllemann, M. Wolter, and J. Felsberg Frequent promotor hypermethylation and low expression of the MGMT gene in oligodendroglial tumours Int J Cancer 113 2004 379 385
48. J.G. Cairncross, K. Ueki, and M.C. Zlatescu Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas J Natl Cancer Inst 90 1998 1473 1479
49. M.J. van den Bent, L.H.J. Looijenga, and K. Langenberg Chromosomal anomalies in oligodendroglial tumours are correlated with clinical features Cancer 97 2003 1276 1284
50. M.J. van den Bent, M.J. Taphoorn, and A.A. Brandes Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglioma: the European Organisation of Research and Treatment of Cancer Brain Tumour Group study 26971 J Clin Oncol 21 2003 2525 2528
51. M.J. van den Bent, O. Chinot, and W. Boogerd Second-line chemotherapy with Temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumour Group phase II study 26972 Ann Oncol 14 2003 599 602
52. V. Triebels, M.J.B. Taphoorn, and A.A. Brandes Response to 2nd line PCV chemotherapy in recurrent oligodendroglioma after 1st line temozolomide Neurology 63 2004 904 906
53. J.G. Cairncross, W. Seiferheld, and E. Shaw An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas: initial report of RTOG 94-02 Proc Am Soc Clin Oncol 23 2004 107 (Abstract # 1500)
54. M. Klein, J.J. Heimans, and N.K. Aaronson Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study Lancet 360 2002 1361 1368
55. M. Brada, L. Viviers, and C. Abson Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas Ann Oncol 14 2003 1715 1721
56. E. Biemond-ter Stege, J.M. Kros, and H.G. de Bruin Treatment of low-grade oligodendroglial tumours with PCV chemotherapy Cancer 103 2005 802 809
57. J.C. Buckner, D. Gesme, and J.R. O'Fallon Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and and associations with chromosomal abnormalities J Clin Oncol 21 2003 251 255
58. K. Hoang-Xuan, L. Capelle, and M. kujas Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions J Clin Oncol 22 2004 3133 3138
59. A. Pace, A. Vidiri, and E. Galie Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response Ann Oncol 14 2003 1722 1726
60. J.A. Quinn, D.A. Reardon, and A.H. Friedman Phase II trial of temozolomide in patients with progressive low-grade glioma J Clin Oncol 21 2003 646 651
61. A.A. Brandes, A. Tosoni, and P. Amista How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial Neurology 63 2004 1281 1284
62. A.A. Brandes, A. Tosoni, and U. Basso Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) J Clin Oncol 22 2004 4779 4786
63. A.C. Kappele, T.J. Postma, and M.J. Taphoorn PCV chemotherapy for recurrent glioblastoma multiforme Neurology 56 2001 118 120